<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282555</url>
  </required_header>
  <id_info>
    <org_study_id>HEC/STU(-Na)05816N/TU 2.05</org_study_id>
    <nct_id>NCT00282555</nct_id>
  </id_info>
  <brief_title>Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis</brief_title>
  <official_title>Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>STEBA France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>STEBA France</source>
  <brief_summary>
    <textblock>
      STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric
      acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
      This trial aims to find out the therapeutic dose of STU-Na required for healing patients with
      erosive or ulcerative esophagitis. One of four dosages of STU-Na (15 mg, 30 mg, 60 mg, or 90
      mg daily), or Esomeprazole 40 mg daily, an already marketed PPI, will be given to patients.
      The attribution to one of the 5 treatment groups will be by chance. Neither the patient nor
      the study physician will know, which treatment is administered to the patient.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>February 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal endoscopy: assessment of achievement of grade &quot;not present&quot; in the Los Angeles scale of esophagitis after two weeks of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal endoscopy: assessment of achievement of grade &quot;not present&quot; in the Los Angeles scale of esophagitis after four weeks of treatment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of complete relief of heartburn</measure>
  </secondary_outcome>
  <enrollment>450</enrollment>
  <condition>Esophagitis, Reflux</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Tenatoprazole-Na (STU-Na)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients aged 18 to 75 years inclusive

          -  Symptomatic ulcerative or erosive esophagitis

          -  Presence of heartburn (daytime and/or nighttime).

          -  Understanding the study and agreeing to give a written informed consent

          -  Able to communicate well with the investigator him(her)self or his/her representatives

          -  Able and agreeing to comply with all study requirements

        Exclusion Criteria:

          -  gastrointestinal bleeding

          -  gastric or esophageal surgery

          -  Zollinger-Ellison syndrome

          -  primary esophageal motility disorders,

          -  esophageal stricture,

          -  inflammatory bowel disease,

          -  upper gastrointestinal malignancy,

          -  pancreatitis,

          -  malabsorption

          -  Barrett's esophagus (&gt; 3 cm)

          -  Severe disease/condition such as malignancy

          -  Hypersensitivity to PPIs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Thomson, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alberta, Division of Gastroenterology, Department of Medicine, Edmonton, Alberta, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abbottsford</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Charles-de-Borromée</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Armstrong D. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:19-26; discussion 38-9. Review.</citation>
    <PMID>15456460</PMID>
  </reference>
  <reference>
    <citation>Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51 Suppl 1:59-67.</citation>
    <PMID>1397746</PMID>
  </reference>
  <reference>
    <citation>Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990 Aug;99(2):345-51.</citation>
    <PMID>2142113</PMID>
  </reference>
  <reference>
    <citation>DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999 Jun;94(6):1434-42.</citation>
    <PMID>10364004</PMID>
  </reference>
  <reference>
    <citation>Galmiche JP, Bruley Des Varannes S, Ducrotté P, Sacher-Huvelin S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.</citation>
    <PMID>15023167</PMID>
  </reference>
  <reference>
    <citation>Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther. 2000 Mar;22(3):266-80; discussion 265. Review.</citation>
    <PMID>10963283</PMID>
  </reference>
  <reference>
    <citation>Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005 Sep;100(9):1949-56.</citation>
    <PMID>16128938</PMID>
  </reference>
  <reference>
    <citation>Kakinoki B, Ono C, Yamazaki N, Chikamatsu N, Wakatsuki D, Uchiyama K, Morinaka Y. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine. Methods Find Exp Clin Pharmacol. 1999 Apr;21(3):179-87.</citation>
    <PMID>10389120</PMID>
  </reference>
  <reference>
    <citation>Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2004 Aug 15;20(4):399-406.</citation>
    <PMID>15298633</PMID>
  </reference>
  <reference>
    <citation>Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology. 1999 Aug;59(2):57-77. Review.</citation>
    <PMID>10450061</PMID>
  </reference>
  <reference>
    <citation>Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80.</citation>
    <PMID>10403727</PMID>
  </reference>
  <reference>
    <citation>Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999 Dec;13(12):1621-30.</citation>
    <PMID>10594397</PMID>
  </reference>
  <reference>
    <citation>Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000 Aug;14(8):963-78. Review.</citation>
    <PMID>10930890</PMID>
  </reference>
  <reference>
    <citation>Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999 Apr;51(4):457-64.</citation>
    <PMID>10385219</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2006</study_first_posted>
  <last_update_submitted>March 18, 2008</last_update_submitted>
  <last_update_submitted_qc>March 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2008</last_update_posted>
  <keyword>Esophagitis, Reflux</keyword>
  <keyword>S-Tenatoprazole-Na</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Esophageal endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

